Shareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced they are convening an extraordinary general meeting of shareholders (“EGM”). The shareholders convening the meeting (the “Convening Shareholders”) include Yi Zhang, the founder of YS Biopharma and a director, who (as of February 8, 2024) beneficially owns approximately 52% of the issued and outstanding ordinary shares of YS Biopharma through the acting-in-concert arrangement.
The EGM will be held on February 16, 2024. The purpose of the EGM is to remove six current members of YS Biopharma’s board of directors and to elect four new directors. YS Biopharma shareholders of record as of February 8, 2024 (the “record date”) are entitled to notice of and to vote at the EGM.
The notice of meeting and related materials are attached to this press release.
Please download here :
https://console.box.lenovo.com/l/p1RjNO
https://docs.google.com/document/d/1y3Pt1hGRw_E1rb7-0cjgK54-ilKJ8aYt/edit?usp=sharing&ouid=104544428354905611038&rtpof=true&sd=true
Cautionary Statement Regarding Forward-Looking Statements
This press release (including its attachments) contains “forward-looking statements.” All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the EGM, the leadership of YS Biopharma, its ability to develop and commercialize current and planned products, its research and development efforts and other matters regarding business strategies, results and plans and objectives for future operations. These statements are based on the beliefs and assumptions of the Convening Shareholders and on information currently available to them, which is based in part on information provided by YS Biopharma’s board of directors and management. Although the Convening Shareholders believe that they have a reasonable basis for such statements, these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, events or achievements to differ materially from the information expressed or implied by these statements. These risks, uncertainties and other factors include the possibility of undisclosed actions by members of the YS Biopharma board of directors and management, potential efforts to dilute shareholders, the prospect of litigation, the potential for potential defaults or enforcement by the creditors of YS, and other risks, uncertainties and factors described under the headings “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents filed by YS Biopharma with the U.S. Securities and Exchange Commission or in public statements by the Convening Shareholders from time to time. Forward-looking statements may not prove to be accurate. The forward-looking statements in this press release speak as of the date hereof, and the Convening Shareholders undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Urban Flash News journalist was involved in the writing and production of this article.